AML
News
Drug granted breakthrough designation for AML
Image by Lance Liotta The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for CPX-351 (Vyxeos), a fixed-ratio...
News
Breast cancer drug could treat AML
(below) palbociclib treatment Images courtesy of Iris Uras and Vetmeduni Vienna Palbociclib, a CDK4/6 kinase inhibitor approved to treat breast...
Article
On the road to harnessing CRISPR gene editing to treat cancer
News
Manipulating a microRNA to treat AML
Image by Su Jung Song The microRNA miR-22 is “an essential antitumor gatekeeper” in acute myeloid leukemia (AML), researchers have reported in...
News
Childhood cancer risk linked to mother’s birthplace
Photo by Nina Matthews New research suggests a mother’s birthplace may affect the risk of certain cancers for Hispanic children. The study...
Conference Coverage
Change in T-cell distribution predicts LFS, OS in AML
NEW ORLEANS—A phase 4 study has revealed biomarkers that appear to predict the efficacy of treatment with histamine dihydrochloride (HDC) and...
News
Donor EBV status affects recipient graft-vs-host disease risk
Key clinical point: In allogeneic hematopoietic stem-cell transplantation, the donor’s EBV status affects the recipient’s risk of developing GVHD...
News
Targeted corticosteroids cut GVHD incidence
The key to selecting patients most likely to benefit from corticosteroid therapy is to identify those at high risk for GVHD using high levels of...
News
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
In myelodysplastic syndrome, improved tool for predicting death after HCT
Key clinical point: A portion of patients with myelodysplastic syndrome in high- and very high–risk groups of the revised International Prognostic...